Abstract OBJECTIVES: Transcatheter procedures have overtaken conventional operations in Germany. Considering that this is a highly competitive field, a rate of 25% for minimal access aortic valve replacement seems to be disappointingly low. One way to promote minimal access techniques is through the systematic use of rapid deployment valves.
INTRODUCTION
Transcatheter aortic valve procedures strongly influence the number of patients who are referred for conventional aortic valve replacement (AVR) in Germany. Meanwhile, conventional operations are outnumbered by transcatheter procedures [1] . Excellent short-term and intermediate-term results justify a further expansion of indications to intermediate-risk populations [2] [3] [4] .
Considering that this is a highly competitive field, a rate of 25% for minimal access AVR seems to be disappointingly low [1] .
Many concerns exist regarding increased cardiopulmonary bypass and myocardial ischaemic times. The positive effects of minimal access techniques such as shorter ventilation times, shorter intensive care unit and hospital lengths of stay, less blood loss, faster return to routine life activities and cosmetic effects might be outweighed [5, 6] .
Two different valve systems aimed at procedural simplification are currently available for conventional AVR: Perceval S valve system (LivaNova Sorin Group, Sallugia, Italy) and the Edwards INTUITY valve system (Edwards Lifesciences Corp., Irvine, CA, USA) [7, 8] . Recent studies have shown reproducible short myocardial ischaemic and cardiopulmonary bypass times, along with superior haemodynamic performance, low paravalvular leakage and pacemaker rates [7] [8] [9] [10] .
The lack of intermediate and long-term data concerning minimally invasive rapid deployment AVR has prompted us to initiate this study.
This series presents operative data and intermediate outcomes.
MATERIALS AND METHODS
A non-randomized single-centre study was conducted to monitor initial and long-term outcomes after minimal access †Presented at the 31st Annual Meeting of the European Association for CardioThoracic Surgery, Vienna, Austria, 7-10 October 2017. rapid deployment AVR. The ethical review board of the RuhrUniversity Bochum approved the study, and informed consent was obtained from all patients (Reg. No. .
The Edwards INTUITY valve is a bovine pericardial valve based on the Edwards perimount family of valves. It is mounted on a balloon-expandable stent frame to anchor the valve in the left ventricular outflow tract [7, 10] . In 2014, a new generation of rapid deployment valves was introduced: the Edwards INTUITY elite valve system, with additional sealing features and a flexible delivery device.
The size of the trial was based on the TRITON pivotal trial (n = 146) [7] .
A total of 143 patients received rapid deployment AVR via upper right hemisternotomy between March 2012 and September 2015. Either the 1st or the 2nd generation of the Edwards INTUITY valve system was used.
The inclusion criteria for rapid deployment AVR were as follows: severe aortic valve stenosis defined by a valve area <1.0 cm 2 . The exclusion criteria were pure aortic insufficiency (AI); aneurysmal dilatation (45 mm) or dissection of the ascending aorta, active endocarditis, bicuspid aortic valve and recent myocardial infarction (<90 days).
The mean age was 76.4 ± 6.2 years, and the mean logistic EuroSCORE was 11.0 ± 4.3% (Table 1) .
The technique has been described previously and is shortly recapitulated [10] . At our institution, hemisternotomy is the standard access for isolated AVR in addition to right anterior thoracotomy.
A standard j-shaped partial sternotomy into the 2nd, 3rd or 4th right intercostal space was performed, with direct cannulation of the aorta and the right atrial appendage. Cardioplegia was administered in an antegrade fashion using cold blood cardioplegia. Venting of the ventricle was performed through the right upper pulmonary vein. The aortic valve was exposed through a standard hockey stick aortotomy. The aortic valve was excised, followed by decalcification of the annulus. After the sizing procedure, the rapid deployment valve was brought into position using 3 guiding sutures at each nadir of the native sinus. Finally, the balloon catheter was inserted and inflated. The guiding sutures were tied, and the aorta was closed using a typical double-layer technique. Postoperative oral anticoagulant therapy was administered for a 3-month postoperative period in accordance with recent guidelines for the management of patients with valvular heart disease [11] .
Follow-up
All patients were followed up annually. Follow-up data concerning valve-related complications were obtained through telephone interviews with patients, relatives and referring physicians. Data were collected from medical charts (including all data for any suspected complication), autopsy reports or death certificates. Patients who died in the follow-up period were censored. The surviving patients were followed up further. The cumulative follow-up time was 275.2 patient-years, with a median follow-up time of 1.9 years. A follow-up rate of 98% was achieved. Postoperative outcomes were assessed in accordance with the Valve Academic Research Consortium definitions [12] . Echocardiographic assessment of the valve was performed at discharge and after 12 months. The median echocardiographic follow-up time was 13 months.
Echocardiographic analysis
Haemodynamic results were obtained through 2D echocardiography. A total of 135 patients could be assessed echocardiographically. Transvalvular gradients were determined using a Bernoulli equation. Prosthetic aortic regurgitation was classified as none, trivial/trace, mild, moderate or severe according to the recent guidelines [13] . The effective orifice area (EOA) was calculated using the continuity equation [13] .
Statistics
Statistical analysis was performed using SPSS 24.0 statistical software. Continuous variables are presented as mean and standard deviation. Categorical variables are summarized as the number and percentage of subjects in each category. The sample size was chosen to reflect the study size of the TRITON pivotal trial (n = 146). The primary end-point was a combined end-point (major cardiac adverse event) including exploratory end-points such as all-cause mortality, reoperation, thromboembolism, valve thrombosis, major paravalvular leak (>2+), bleeding events, myocardial infarction and endocarditis. One-year and 3-year KaplanMeier estimates were computed for the combined end-point as well as for all exploratory outcomes. A standard confidence level of 95% was chosen. Early event rates (<30 days postoperatively) were calculated as the number of events divided by the total number of subjects receiving implants, expressed as a percentage. Late events (>30 days postoperatively) were summarized using linear rates (% per patient-year) and calculated by dividing the number of late events by the sum of patient years.
RESULTS

Operative data
The mean cross-clamp time was 36 ± 19 min, and the mean cardiopulmonary bypass time was 62 ± 15 min (Table 2) . A mean valve implantation time, as defined by the interval between the first annular stitch and the last guiding suture being tied, was 10 ± 5 min. An overall procedural success rate of 99.3% (142 of 143 patients) was seen. One patient showed severe paravalvular leakage, with resulting Grade 3 AI in the intraoperative transoesophageal echo examination. The rapid deployment valve had to be replaced with the conventional stented pericardial valve (Edwards Perimount TM ).
Early and late morbidity and mortality
Early all-cause mortality was 2.7% (4 of 143 patients) ( Table 3 ). The specific causes for early mortality were pericardial tamponade (n = 1), systemic inflammatory response syndrome with multiorgan failure (n = 2) and intestinal ischaemia (n = 1). Thrombembolic events occurred in 3 (2.0%) patients, including 2 non-fatal strokes and 1 fatal intestinal ischaemia. Further complications were major bleeding requiring rethoracotomy in 7 patients, major PVL (>2+) in 2 patients, pacemaker implantation in 6 patients and valve explantation in 3 patients. Early valve explantation had to be performed because of major paravalvular leak (PVL) (>2+) in 2 cases and bleeding in 1 case. One case of PVL occurred intraoperatively and 1 case 3 days after the operation. A luxation of the non-coronary portion of the rapid deployment valve occurred. Both valves were explanted and replaced with conventional pericardial valves. Pericardial tamponade led to cardiopulmonary resuscitation in 1 patient. Mechanical compression caused deformation of the subannular stent frame resulting in severe AI. The valve was explanted and replaced. The outcome was fatal. No cases of deep sternal wound infection were seen in the early and or late postoperative period.
Fifteen patients died during the follow-up period (5.4% per patient-year). The causes of late mortality were urogenital infection with consecutive sepsis in 2 patients, stroke in 1 patient, cardiac arrest in 1 patient, endocarditis in 1 patient, pneumonia with respiratory failure in 2 patients, traumatic cerebral haemorrhage in 1 patient, multiorgan failure after abdominal surgery in 1 patient, ruptured abdominal aortic aneurysm in 1 case and intestinal ischaemia in 1 patient. The cause of death remained unclear in 4 cases. Overall actuarial survival at 1 year was 91.6 ± 2.4% and 84.4 ± 3.6% at 3 years, respectively (Fig. 1) .
Six major thromboembolic events occurred (2.1% per patientyear). Permanent neurological deficit occurred in 3 patients. Two thromboembolic events were fatal (0.7% per patient-year).
Freedom from stroke at 1 year was 95.1 ± 1.8% and 93.2 ± 2.1% at 3 years, respectively (Fig. 2) . Late endocarditis was seen in 1 case (0.4% per patient-year), and reoperation had to be performed. The outcome was fatal. This was the only cause for late valve explantation and reoperation as well as major paravalvular leakage (0.4% per patient-year) Valve-related thrombosis, haemolysis and structural valve deterioration did not occur during the follow-up period. Freedom from major cardiac events after 1 year was 81.1 ± 2.9% and 77.1 ± 3.5% at 3 years, respectively (Fig. 3) .
Echocardiographic data
Echocardiographic results stratified by valve size are summarized in Tables 4 and 5 . The mean EOA at discharge was 1.8 ± 0.3 cm 2 and 1.8 ± 0.3 cm 2 after 12 months. Mean transprosthetic gradients were 11.4 ± 4.3 mmHg at discharge and 10.3 ± 3.8 mmHg after 12 months. A total of 115 patients (85.1%) did not show any paravalvular leakage at discharge. Paravalvular leakage occurred in 20 cases with resulting Grade 1+ AI (trivial/trace) in 16 (11.8%) patients and Grade 2+ AI (mild) in 4 (2.9%) patients. No major paravalvular leakage occurred. A total of 17 patients presented with paravalvular leakage during the 12-month follow-up echo. Fourteen (11.2%) cases were classified as Grade 1+ AI (trivial/ trace) and 3 cases as 2+ AI (mild). All leaks were primarily registered in the discharge echo. New cases of paravalvular leakage were not seen during the 12-month follow-up. One case of major paravalvular leakage (>2+) occurred in the complete follow-up period due to endocarditis (0.4% per patient-year).
DISCUSSION
A central issue of contemporary cardiovascular medicine is a clear tendency towards less invasive procedures. The drive to Data are presented as n (%) for early events, n (% per patient-year) for late events and mean ± standard deviation for actuarial freedom from event after 3 years.
preserve maximum physical integrity is considered to be one of the standard basic human needs in this context and must not be underestimated in a highly competitive variety of therapeutic options. Standard AVR via median sternotomy runs a risk of being passed over by referring physicians and patients despite its gold standard status in view of its excellent long-term results for low-and intermediate-risk patients. With a minimal access surgery penetration as low as 25%, further promotion and improvement of minimal access techniques in aortic valve surgery is mandatory [1] . A typical feature of the Edwards INTUITY valve system, the balloon-expandable stent frame, which anchors the valve in the left ventricular outflow tract, confers several benefits. The subannular design translates to an optimized EOA while facilitating the implantation process [7, 9, 10] . Therefore, the combination of excellent haemodynamic properties and accelerated implantation in a minimal access setting can be considered a complementary association of technique and technology.
Higher rates of prosthesis-patient mismatch (PPM) were seen in PARTNER 1 for conventional AVR than for transcatheter aortic valve implantation [14] . Therefore, Pibarot et al. [15] suggested transcatheter aortic valve implantation to prevent PPM in intermediate-and high-risk patients with small aortic roots. However, significantly higher rates of moderate-severe paravalvular leakage occurred in the transcatheter group, which significantly influences left ventricular mass regression and survival [15] . This might outweigh the benefits of haemodynamic superiority. Recently, Theron et al. [16] demonstrated low rates of PPM (15%), together with low rates of moderate-severe paravalvular leakage (1.5%), after rapid deployment AVR in patients with small aortic roots. Severe PPM was even less frequent than in the transcatheter subgroup of the PARTNER 1 cohort reported by Pibarot et al. [15] (15% vs 19%) [16] .
This superior haemodynamic performance is complemented by the well-studied durability of the Carpentier-Edwards PERIMOUNT pericardial aortic prosthesis. Johnston et al. [17] recently published a study of 12 569 patients who underwent AVR with the PERIMOUNT valve during a 27.5-year period. Kaplan-Meier estimates for structural valve deterioration at 10 and 20 years were 1.9% and 15%, respectively. Some distinct advantages for minimal access AVR were reported, including shorter intensive care unit and hospital lengths of stay, less blood loss and faster return to routine life activities [18] . Randomized prospective studies confirmed the safety of the approach despite consistently reported prolonged operative times [18] [19] [20] . Cross-clamp and cardiopulmonary 12.2 ± 3.8 (n = 45) 10.9 ± 3.1 (n = 42) 23 11.1 ± 3.1 (n = 35) 10.1 ± 3.3 (n = 32) 25 9.5 ± 3.0 (n = 34) 9.2 ± 3.0 (n = 33) 27 8.5 ± 2.9 (n = 15) 7.3 ± 3.1 (n = 13) EOA Overall, mean ± SD 1.8 ± 0. bypass times have to be considered as independent predictors of morbidity and mortality after cardiac surgery [5, 6] . Borger et al. [9, 21] found that reduced cross-clamp and cardiopulmonary bypass times did not necessarily translate into improved postoperative and 1 year follow-up outcomes concerning mortality in a prospective randomized trial. Nevertheless, no inferior results were seen, while the echocardiographic performance was superior to conventional aortic valves. In a first series of 60 patients, we could demonstrate that minimal access AVR can be performed safely with reproducibly short cross-clamp and cardiopulmonary bypass times. A mean crossclamp time of 26 ± 7 min along with a mean cardiopulmonary bypass time of 56 ± 12 min and a 30-day mortality rate of 1.7% were described [10] . In the following series, the cross-clamp and cardiopulmonary bypass times increased up to 36 ± 19 min and 62 ± 15 min, respectively. Mortality was 2.7%. This increase might be explained by a larger number of surgeons routinely implanting rapid deployment valves in this study compared with the initial 60 patients. However, a clear potential of the Edwards INTUITY valve system to accelerate minimal access procedures can be stressed. Borger et al. [9] found mean cross-clamp times of 41.3 ± 20.3 min in the minimal access group, which meant a reduction of 13% compared with the CADENCE-MIS study. Cross-clamp times of 49.3 ± 26.9 min for full sternotomy and 63.1 ± 25.4 min for minimal access surgery were recently published for the TRANSFORM pivotal trial in the USA [22] . A minimal access rate of 60% was achieved in this study. Cross-clamp times of 41.1 ± 10.6 min for isolated AVR were seen in the TRITON pivotal trial in Europe [7] . Herein, minimal access AVR was performed in 48.8% of the isolated AVR cases.
An interesting finding of this study is the lower occurrence of paravalvular leakage compared to other publications, despite the minimal access setting. A minor paravalvular leakage rate (1+ or 2+) of 14.7% (confidence interval 0.093-0.219) was seen at discharge, which remained stable at 1 year with 13.6% (confidence interval 0.081-0.209). No case of higher grade leakage (>2+) was seen in the routine follow-up echo examinations. Borger et al. [21] described a rate of 21% for minor leakage (1+ or 2+) at discharge and 33% at 1 year with significantly more leaks compared with standard aortic valves. Haverich et al. [23] found a rate of 35.8% at 1 year and 43.6% at 3 years. In both studies, minor leakage rates at 1 year were clearly outside the 95% confidence interval. A tendency towards lower rates of PVL can be stressed. Barnhart et al. [22] reported 2+ leakage rates of 6.9% for the recent TRANSFORM trial in the USA, which is clearly above the European rates. The lower occurrence of paravalvular leakage might be explained by the exhaustive experience with rapid deployment valve implantation in our institution, while recent studies often represent the beginning of a learning curve in a multicentre setting. Decalcification and sizing are the most sensitive parts of the operation. Excessive decalcification should be avoided because annular defects cannot be sealed with valve sutures. Defects or non-cylindrical distortions as a result of the decalcification procedure may lead to paravalvular leaks or annular rupture. Some extra sutures can be placed in the area of the annular defect to prevent leakage. Exact sizing is essential. Oversizing may cause luxation during balloon inflation and undersizing may cause paravalvular leakage. Severe leakage (>2+) was caused by undersizing (1st generation of the valve) or improper decalcification of the acoronary annulus and the anterior mitral leaflet leading to luxation (2nd generation of the valve). Minor leakage rates of 4% were described for the Perceval S Valve [24] . Since quantification of leaks in 2D echocardiography is limited, 3D echocardiography should be involved in future studies.
The haemodynamic characteristics of the Edwards INTUITY valve system in this study are almost similar to the performance of the Carpentier-Edwards PERIMOUNT valve. Dellgren et al. [25] and Dalmau et al. [26] found mean gradients of 12.3 ± 4.8 mmHg and 10.3 ± 3.4 mmHg, respectively, in the echocardiographic follow-up at 1 year. The mean transvalvular pressure gradients of 10.3 ± 3.8 mmHg in this study seem to match with recent echocardiographic findings. Randomized trials have demonstrated significantly better haemodynamic performance in terms of pressure gradients and EOA, which might be explained by the flared configuration without pledges in the outflow tract [9, 21] .
Early pacemaker rates of 4.2% (6 of 143 patients) are in line with the results previously published for the INTUITY valve system (4.3-11.9%) and for conventional AVR (3.0-11.8%) [7, 9, 22, 27] .
Actuarial survival rates of 91.6 ± 2.4% at 1 year and 84.4 ± 3.6% at 3 years showed no excess mortality compared with commonly used tissue valves [25, 26] .
Linearized thromboembolism rates of 2.1% per patient-year, bleeding rates of 1.1% per patient-year and endocarditis rates of 0.4% per patient-year were comparable to conventional pericardial valves [25, 28] . Some concerns exist that subvalvular cuff material may lead to increased endocarditis rates, which was not seen within this intermediate period.
This study focused on the evaluation of rapid deployment valves in minimally invasive surgery. In addition to this specific indication, the Edwards INTUITY valve system is widely used in combined procedures with concomitant bypass surgery or in a multiple valve setting [27, 29] . Possible indications are a high/ intermediate risk profile, low ejection fraction, hypercalcified aortic annulus, multiple valve disease and coronary heart disease.
Limitations
This was a non-randomized, single-centre observational study without a concurrent control group. A non-blinded study design may lead to selection and performance biases in addition to attrition biases resulting from missing data points.
CONCLUSION
Minimal access rapid deployment AVR can be performed safely with low complication rates and low rates of paravalvular leakage in an intermediate risk patient cohort. New onset of paravalvular leakage in the postoperative follow-up has occurred so far. Good follow-up outcomes underline the relevance of this evolving technique in the promotion and dissemination of minimal access aortic valve surgery.
